William B. Hillegass

Author

University of Alabama at Birmingham ORCID

Also Known As

Greene, Casey S, Hillegass, William B., Jeffrey Shenberger, M.H. Premkumar, W. B Hillegass, W. B. Hillegass, W. Hillegass, W.B. Hillegass, Will Cooper, William B Hillegass

230

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

University of Alabama at Birmingham University of Mississippi Medical Center Jackson Memorial Hospital Vanderbilt University Medical Center Duke Medical Center

About

William B. Hillegass is an author at University of Alabama at Birmingham specializing in medicine, cardiovascular disease, and coronary heart disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	16	1.6K
2	Public Health	5	5	176
3	Health Sciences	2	2	153
4	Language Studies	1	1	84
5	Applied Physiology	1	1	88

William B. Hillegass

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial Robert J. Lederman, Farrell O. Mendelsohn, R. David Anderson, The Lancet Regenerative MedicineThrombosisTranslational MedicineAngiogenesisCardiovascular Disease	2002	513
Adoption of Radial Access and Comparison of Outcomes to Femoral Access in Percutaneous Coronary Intervention Dmitriy N. Feldman, Rajesh V. Swaminathan, Lisa A. Kaltenbach, Circulation	2013	461
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention Larisa H. Cavallari, Craig R. Lee, Amber L. Beitelshees, JACC: Cardiovascular Interventions Percutaneous Coronary InterventionThrombosisMultisite InvestigationCardiovascular DiseaseBlood Platelet	2017	303
Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative Tellen D. Bennett, Richard A. Moffitt, Janos Hajagos, JAMA Network Open	2021	239
Relation Between Activated Clotting Time During Angioplasty and Abrupt Closure Craig R. Narins, William B. Hillegass, Charlotte Nelson, Circulation	1996	189
The Learning Curve for Transradial Percutaneous Coronary Intervention Among Operators in the United States Connie N. Hess, Eric D. Peterson, Megan L. Neely, Circulation	2014	167
The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis Jie Zhang, Lang Chen, Elizabeth Delzell, Annals of the Rheumatic Diseases	2014	164
Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience William B. Hillegass, Neal A Dean, Laurence Liao, Journal of the American College of Cardiology Percutaneous Coronary InterventionCardiovascular DiseaseImpaired FlowEndothelial DysfunctionPercutaneous Coronary Interventions	2001	162
Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention Thaddeus R. Tolleson, J.Conor O’Shea, John A. Bittl, Journal of the American College of Cardiology ThrombosisPercutaneous Coronary InterventionHeparin AnticoagulationCardiovascular DiseaseCoronary Artery Disease	2003	106
Effects on platelet aggregation and fibrinolytic activity during upright posture and exercise in healthy men K. Winther, William B. Hillegass, Geoffrey H. Tofler, The American Journal of Cardiology Upright PosturePhysical ActivityKinesiologyFibrinolytic ActivityExercise	1992	88

Page 1